The startup develops cell and gene therapies aimed at cardiac regeneration to restore muscle mass and contractile strength in patients with chronic heart disease. By targeting the underlying mechanisms of heart failure, the company seeks to reverse the progression of this condition and improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic heart failure affects millions and is a leading cause of death, yet curative treatments are lacking. The heart's limited capacity for self-regeneration hinders recovery from heart attacks and age-related muscle loss, leading to diminished cardiac function.
Solution
StemCardia is developing cell and gene therapies designed to regenerate and strengthen heart muscle tissue, addressing the unmet need for curative treatments for heart failure. The company's approach focuses on re-muscularizing the failing heart through the transplantation of pluripotent stem cell-derived cardiac muscle cells and genetic enhancement. By leveraging bioreactors to produce clinically relevant quantities of cardiac cells, StemCardia aims to restore cardiac function and improve outcomes for patients suffering from heart failure. Their therapies are designed for commercial development and outpatient administration, ensuring broad accessibility.
Target Audience
The primary target audience includes patients diagnosed with heart failure, cardiologists, and medical centers focused on advanced heart failure treatments.
Features
- Cell replacement therapies using induced pluripotent stem cells (iPSCs) to regenerate heart muscle
- Gene therapies to strengthen heart muscle contraction
- Bioreactor-based manufacturing for large-scale production of cardiac cells
- Off-the-shelf technologies suited to commercial development and outpatient administration
- Focus on safety and efficacy studies to gain FDA approval for clinical trials